Sales growth at constant exchange rates
European Union · Q1 2026
Sales growth at constant exchange rates in the European Union came in at 1% in Q1 2026 (Roche).
- Publisher
- Roche
- Authority tier
- T2 National
- Locator
- Group results
- Retrieved
- 15 Sep 2026
- Status
- Verified
What the source says
Sales in Europe were +1% at CER, or -1% when reported in CHF, as demand for Ocrevus, Evrysdi (spinal muscular atrophy) and Phesgo more than offset the impact of lower sales of Actemra/RoActemra due to biosimilar competition and Perjeta because of the conversion of patients to Phesgo.
The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.
- APA
- Roche. (2026). [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a.... Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-07-23. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE9
- MLA
- Roche. "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...." 2026, https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE9.
- Chicago
- Roche. "[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...." 2026. https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE9.
- BibTeX
- @misc{roche2026salesbjmge9, author = {{Roche}}, title = {[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6\% sales growth at constant exchange rates; -2\% in CHF due to the significant a...}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE9}, note = {Original source: https://www.roche.com/media/releases/med-cor-2026-07-23. Accessed September 15, 2026.} }
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Primary Source
- Publisher
- Roche · homepage ↗
- Authority tier
- Tier 2 · National Official
- Report
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant a...
- Type
- Press release
- Published
- 23 July 2026
- Locator
- Group results
- Retrieved
- 15 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification & Integrity
- Audit status
- Verified
- Review protocol
- Editorial review
- Checked on
- 15 September 2026
- Last revision
- 15 September 2026
- Archival URI
- /stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGE9